{"filing":{"accession_number":"0001213900-26-061028","cik":"0001191070","ticker":"NEUP","company_name":"Neuphoria Therapeutics Inc.","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"ea0292160-8k_neuphoria.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1191070/000121390026061028/ea0292160-8k_neuphoria.htm"},"events":[{"id":9065,"run_id":7960,"accession_number":"0001213900-26-061028","anchor_item_number":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Neuphoria received a material revenue distribution of AUD $1.416M (approximately USD ~$950K) from its participation in the Cancer Therapeutics CRC related to Pfizer's KAT6 program milestone. The company also disclosed it is eligible to receive approximately 4.65% of future milestone payments estimated at USD $460M total across all parties. While this is a revenue/milestone event, it does not fit cleanly into earnings_release (no quarterly/annual results disclosure) or other standard categories, making other_material the most appropriate classification for this passive participation in a third-party licensing arrangement with contingent future payments.","company_name":"Neuphoria Therapeutics Inc.","ticker":"NEUP","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":1552,"accession_number":"0001213900-26-061028","item_number":null,"item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Neuphoria received a material revenue distribution of AUD $1.416M (approximately USD ~$950K) from its participation in the Cancer Therapeutics CRC related to Pfizer's KAT6 program milestone. The company also disclosed it is eligible to receive approximately 4.65% of future milestone payments estimated at USD $460M total across all parties. While this is a revenue/milestone event, it does not fit cleanly into earnings_release (no quarterly/annual results disclosure) or other standard categories, making other_material the most appropriate classification for this passive participation in a third-party licensing arrangement with contingent future payments.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:14:09.774927+00:00","company_name":"Neuphoria Therapeutics Inc.","ticker":"NEUP","filing_date":"2026-05-26"}]}